

S1 Table. Clinicopathologic correlation of PD-L1 expression in patients with gastric cancers using CPS

| Characteristic | Total | CPS \geq 1 | | | CPS \geq 10 | | |
|-----------------------|------------|--------------|------------|---------|---------------|------------|---------|
| | | Positive | Negative | p-value | Positive | Negative | p-value |
| Age (yr) | | | | | | | |
| < 65 | 251 (66.2) | 139 (63.2) | 112 (70.4) | 0.140 | 23 (62.2) | 228 (66.7) | 0.582 |
| \geq 65 | 128 (33.8) | 81 (36.8) | 47 (29.6) | | 14 (37.8) | 114 (33.3) | |
| Sex | | | | | | | |
| Male | 238 (62.8) | 146 (66.4) | 92 (58.0) | 0.091 | 28 (75.7) | 210 (61.4) | 0.088 |
| Female | 141 (37.2) | 74 (33.6) | 67 (42.0) | | 9 (24.3) | 132 (38.6) | |
| pTNM | | | | | | | |
| II | 180 (47.5) | 106 (48.2) | 74 (46.5) | 0.752 | 25 (67.6) | 155 (45.3) | 0.010 |
| III | 199 (52.5) | 114 (51.8) | 85 (53.5) | | 12 (32.4) | 187 (54.7) | |
| Tumor size (cm) | | | | | | | |
| \leq 5 | 211 (55.7) | 117 (53.2) | 94 (59.1) | 0.251 | 17(45.9) | 194 (56.7) | 0.210 |
| > 5 | 168 (44.3) | 103 (46.8) | 65 (40.9) | | 20 (54.1) | 148 (43.3) | |
| Location | | | | | | | |
| Upper third | 96 (25.3) | 55 (25.0) | 41 (25.8) | 0.158 | 12 (32.4) | 84 (24.6) | 0.695 |
| Middle third | 80 (21.1) | 38 (17.3) | 42 (26.4) | | 5 (13.5) | 75 (21.9) | |
| Lower third | 182 (48.1) | 115 (52.3) | 67 (42.1) | | 19 (51.4) | 163 (47.6) | |
| GEJ | 5 (1.3) | 2 (0.9) | 3 (1.9) | | 0 | 5 (1.5) | |
| Entire | 16 (4.2) | 10 (4.5) | 6 (3.8) | | 1 (2.7) | 15 (4.4) | |
| WHO | | | | | | | |
| WD | 5 (1.3) | 3 (1.4) | 2 (1.3) | 0.208 | 0 (0.0) | 5 (1.5) | < 0.001 |
| MD | 116 (30.6) | 73 (33.2) | 43 (27.0) | | 8 (21.6) | 108 (31.6) | |
| PD | 159 (42.0) | 89 (40.5) | 70 (44.0) | | 24 (64.9) | 135 (39.4) | |
| PCC(SRC) | 93 (24.5) | 49 (22.3) | 44 (27.7) | | 2 (5.4) | 91 (26.6) | |
| UD | 1 (0.3) | 1 (0.5) | 0 | | 1 (2.7) | 0 | |
| GCLS/ADSQCA | 5 (1.3) | 5 (2.3) | 0 | | 2 (5.4) | 3 (0.9) | |
| Lauren classification | | | | | | | |
| Intestinal | 135 (35.6) | 87 (39.5) | 48 (30.2) | 0.101 | 13 (35.1) | 122 (35.7) | 0.007 |
| Diffuse | 213 (56.2) | 113 (51.4) | 100 (62.9) | | 17 (45.9) | 196 (57.3) | |
| Mixed | 29 (7.7) | 18 (8.2) | 11 (6.9) | | 5 (13.5) | 24 (7.0) | |
| Indeterminate | 2 (0.5) | 2 (0.9) | 0 | | 2 (5.4) | 0 | |
| Ming's classification | | | | | | | |
| Infiltrative | 307 (81.0) | 166 (75.5) | 141 (88.7) | 0.001 | 13 (35.1) | 294 (86.0) | < 0.001 |
| Expanding | 72 (19.0) | 54 (24.5) | 18 (11.3) | | 24 (64.9) | 48 (14.0) | |
| Lymphatic invasion | | | | | | | |
| Absent | 118 (31.1) | 62 (28.2) | 56 (35.2) | 0.144 | 10 (27.0) | 108 (31.6) | 0.570 |
| Present | 261 (68.9) | 158 (71.8) | 103 (64.8) | | 27 (73.0) | 234 (68.4) | |
| Vascular invasion | | | | | | | |
| Absent | 319 (84.2) | 180 (81.8) | 139 (87.4) | 0.140 | 35 (94.6) | 284 (83.0) | 0.067 |
| Present | 60 (15.8) | 40 (18.2) | 20 (12.6) | | 2 (5.4) | 58 (17.0) | |
| Perineural invasion | | | | | | | |

| | | | | | | | |
|-----------|------------|------------|------------|-------|-----------|------------|---------|
| Absent | 129 (34.0) | 77 (35.0) | 52 (32.7) | 0.642 | 23 (62.2) | 106 (31.0) | < 0.001 |
| Present | 250 (66.0) | 143 (65.0) | 107 (67.3) | | 14 (37.8) | 236 (69.0) | |
| EBV | | | | | | | |
| Negative | 355 (93.7) | 198 (90.0) | 157 (98.7) | 0.001 | 28 (75.7) | 327 (95.6) | < 0.001 |
| Positive | 24 (6.3) | 22 (10.0) | 2 (1.3) | | 9 (24.3) | 15 (4.4) | |
| p53 | | | | | | | |
| Negative | 277 (73.1) | 161 (73.2) | 116 (73.0) | 0.961 | 31 (83.8) | 246 (71.9) | 0.122 |
| Positive | 102 (26.9) | 59 (26.8) | 43 (27.0) | | 6 (16.2) | 96 (28.1) | |
| MSI | | | | | | | |
| MSS/MSI-L | | 191 (86.8) | 153 (96.2) | 0.002 | 27 (73.0) | 317 (92.7) | < 0.001 |
| MSI-H | | 29 (13.2) | 6 (3.8) | | 10 (27.0) | 25 (7.3) | |
| Total | 379 (100) | 220 (58.0) | 159 (42.0) | | 37 (9.8) | 342 (90.2) | |

PD-L1, programmed death ligand 1; CPS, combined positive score; GEJ, gastroesophageal junction; WHO, World Health Organization; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PCC(SRC), poorly cohesive carcinoma (signet ring cell carcinoma); UD, undifferentiated carcinoma; GCLS, gastric carcinoma with lymphoid stroma; ADSQCA, adenosquamous carcinoma; EBV, Epstein-Barr virus; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, MSI-low; MSI-H, MSI-high.